BiotechTube

Pharmacological intensification based on olmesartan

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke, Hypertension

Trial Timeline

Sep 1, 2016 → Dec 7, 2017

NCT ID
NCT03024476

About Pharmacological intensification based on olmesartan

Pharmacological intensification based on olmesartan is a phase 2 stage product being developed by Daiichi Sankyo for Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03024476. Target conditions include Ischemic Stroke, Hypertension.

What happened to similar drugs?

10 of 14 similar drugs in Ischemic Stroke were approved

Approved (10) Terminated (3) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
🔄Milvexian + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03024476Phase 2Completed

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
42
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35
GS-6615 + PlaceboGilead SciencesPhase 1
29